Macrofurin

Quick links to important sections

Macrofurin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Macrofurin

Property Description
Active ingredient Nitrofurantoin
Form Oral Capsule (Dual-release blend)
Pharmacological class Nitrofuran Antibacterial
Common use Killing bacteria in the urinary tract
Origin Synthetic antimicrobial

What Type of Medicine is Macrofurin?

Macrofurin is a prescription-only antibiotic medicine that contains the active ingredient nitrofurantoin. Nitrofurantoin belongs to the Nitrofuran group of antibacterial agents. This classification shows it is a specialized antimicrobial that is clinically recognized for its utility as a frontline agent in its class.

The medicine is a synthetic compound, manufactured to fight bacteria. Unlike many common systemic antibiotics that circulate widely, nitrofurantoin is designed to achieve high, therapeutic concentrations almost exclusively in the urine and urinary tract, making it a highly focused treatment for the adult patient population dealing with urinary issues.

What is Unique About the Capsule’s Formulation?

Macrofurin is typically available as an oral capsule designed for administration by mouth. The capsule is unique because it is formulated with a precise blend of two distinct forms of its single active ingredient: the slower-dissolving macrocrystals and the faster-dissolving monohydrate powder.

This dual composition is designed to promote a smoother, more consistent release of the medicine throughout the digestive system. This controlled-release approach is often pharmacologically supported to help maintain effective levels of the drug in the urine over a longer period, while potentially improving patient tolerance compared to forms that dissolve too rapidly.

What is the General Purpose of Macrofurin?

The general purpose of Macrofurin is to act as a localized antibacterial agent to eliminate susceptible bacteria. It functions by concentrating in the urine and disrupting the essential internal processes bacteria need to survive, which ultimately leads to their destruction. The drug is largely eliminated rapidly through the urinary tract.

By concentrating its power in the urine, Macrofurin provides a powerful and targeted means of resolving bacterial issues. Its primary general function is to clear the bacterial load responsible for issues in the urinary tract, offering a focused and effective solution.

What side effects are possible with Macrofurin?

Macrofurin (nitrofurantoin) is associated with adverse reactions that are classified by frequency and by the affected body system, according to official regulatory standards. The medicine's safety profile includes both common, expected reactions and rare, serious organ-system toxicities.

Frequency and Common Reactions

Reactions classified as common in official labeling include nausea, vomiting, and flatulence. Abdominal pain and diarrhea are also documented. An anticipated, non-harmful effect is the urine turning a yellow or brownish color.

Serious Organ System and Hypersensitivity Reactions

Official documents highlight the potential for severe, organ-specific adverse reactions. Pulmonary reactions (lung toxicity) can be acute, subacute, or chronic, with chronic reactions often associated with therapy lasting six months or longer. Serious hepatotoxicity (liver damage), including hepatitis and hepatic necrosis, and potentially irreversible peripheral neuropathy (nerve damage) are documented. Severe immune responses, such as anaphylaxis and DRESS syndrome, are also officially recognized.

Safety Constraints and Risk Factors

Safety is significantly related to pre-existing conditions and treatment duration. The medicine is contraindicated in patients with significant renal impairment (creatinine clearance less than 60 mL/min), pregnant patients at term, and infants younger than 1 month of age. Renal impairment increases the risk of toxicity, including peripheral neuropathy. Additionally, patients with G-6-PD deficiency are at heightened risk of hemolytic anemia.

Overdose and Emergency Response

Macrofurin Overdose and when to seek help

Overdose Scope

The documented acute overdose manifestations are primarily gastric irritation, nausea, and vomiting. Systemic overexposure carries a risk of severe, potentially irreversible outcomes, including peripheral neuropathy and hepatotoxicity (e.g., hepatic necrosis). An increased risk of toxicity is explicitly stated for patients with significant impairment of renal function (Creatinine clearance under 60 mL/min), Anuria, or Oliguria, which is due to impaired drug excretion. The patient must seek immediate medical attention for suspected overdose or upon the presentation of signs of severe toxicity, which requires immediate discontinuation of the medicine.

Overdose Classifications (High-Level)

The official overdose profile is based on authoritative regulatory documents, such as the Summary of Product Characteristics (SmPC) and Prescribing Information. No known specific antidote is available, constraining management to procedural and supportive measures.

Official Overdose Statements

  • Management involves symptomatic and supportive treatment, including gastric lavage or induction of emesis and maintaining a high fluid intake to promote excretion.
  • Monitoring of Full blood count, Liver function tests, and Pulmonary function tests is recommended during management. Haemodialysis is also listed as an option for recent ingestion.

Connection to the Overall Overdose Profile

The regulatory documents define the overdose response by identifying core gastrointestinal manifestations and mandating urgent help for severe toxicity, especially when impaired renal function is a risk factor. The absence of an antidote dictates that treatment must focus on drug removal procedures, such as gastric lavage, and the strict physiological monitoring of key organ systems to manage potential complications.

Therapeutic Uses of Macrofurin

Macrofurin (nitrofurantoin) is generally used to help manage conditions and symptoms localized within the urinary tract, focusing on conditions involving bacterial activity and providing supportive relief from associated discomfort. The medication is considered relevant for managing acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible bacteria.


Key Therapeutic Focus

Macrofurin is commonly used across conditions presenting with acute episodes of lower urinary tract infection, and it may be relevant for managing recurrent or episodic manifestations as prophylaxis. The medication is applied in clinical settings that involve acute or unstable symptom patterns, addressing conditions involving bacterial activity and offering supportive relief. It is commonly used to help with acute cystitis and managing recurrent UTIs.

The medication helps address symptom clusters that may become intense or disruptive to routine activities, such as painful or burning urination (dysuria), urinary urgency, and frequency. It is helpful in situations where these multiple symptoms occur together, creating noticeable physiological strain.

“Macrofurin supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load during symptomatic periods.”

This therapeutic approach is applied when additional symptomatic support is needed, assists with maintaining a sense of stability when symptoms are more noticeable, and supports general well-being during symptomatic phases.

Quick Fact: Relief for Urinary Discomfort The medication is commonly used to help manage symptoms related to inflammatory or irritative states in the bladder, offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Macrofurin (Nitrofurantoin) eligibility is determined by specific contraindications related to renal function, age, and hypersensitivity, as defined by regulatory agencies.

Contraindicated Populations

The medication must not be used in the following groups due to the risk of toxicity or serious complications:

  • Neonates (infants under one month of age).
  • Pregnant patients at term (38–42 weeks' gestation, labor, or delivery).
  • Patients with severe renal impairment (typically defined as creatinine clearance less than 60 mL/minute), anuria, or oliguria.
  • Individuals with a known allergy or previous hypersensitivity to nitrofurantoin or a history of cholestatic jaundice from the drug.

Restricted or Condition-Specific Use

Use is subject to caution or conditional limitation in specific patient groups:

  • Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: Requires caution due to the risk of hemolytic anemia.
  • Comorbidities: Caution is warranted in patients with conditions like diabetes mellitus, anemia, or electrolyte imbalance, which may increase the risk of peripheral neuropathy.
  • Lactating Patients: Use is restricted when breastfeeding an infant less than one month old or one with G6PD deficiency.

For children aged one month and older, use is generally established, provided renal function is adequate.

What should I know about interactions with other medicines?

This section outlines known interactions for Macrofurin (nitrofurantoin) documented in official regulatory labeling. These interactions can affect how the medicine is absorbed, eliminated, or change its activity or the activity of concomitant medicines.

Interacting Substance/Class Mechanism and Resulting Constraint
Uricosuric Drugs (e.g., probenecid, sulfinpyrazone) These medicines inhibit the renal tubular secretion of Macrofurin, leading to increased levels of Macrofurin in the blood and decreased levels in the urine. This result may increase the risk of Macrofurin-related toxicity while potentially decreasing its efficacy in the urinary tract.
Antacids (Magnesium Trisilicate) Antacid preparations containing magnesium trisilicate significantly reduce the absorption of Macrofurin, likely through an adsorption mechanism in the gastrointestinal tract. Concomitant use with these specific antacids is not recommended.
Quinolone Antimicrobials Official documents note an antagonism demonstrated in laboratory settings between Macrofurin and quinolone antimicrobial agents. The clinical relevance of this finding is currently noted as unknown in the regulatory labeling.

Interaction-Related Procedural Constraint

Macrofurin can interfere with certain laboratory procedures, specifically causing a false positive reaction for glucose in the urine when tested using copper reduction methods.

Mechanism of Action

Macrofurin's active ingredient, nitrofurantoin, requires enzymatic conversion inside the target cell to generate its active components. The parent molecule is reduced by specific bacterial flavoproteins (nitroreductase enzymes, such as NfsA and NfsB). This enzymatic interaction yields highly reactive electrophilic intermediates and free radicals, which are key chemical species involved in macromolecular alteration.

The activated intermediates cause simultaneous and widespread damage across multiple, vital bacterial biosynthetic pathways. These reactive species indiscriminately attack bacterial DNA, leading to strand breaks and replication inhibition, while also inactivating ribosomal proteins and crucial enzymes for aerobic energy metabolism and cell wall synthesis. This multi-target molecular disruption initiates the mechanistic cascade that leads to the cessation of bacterial growth and cellular function.

The mechanism is physiologically constrained because bactericidal concentrations are achieved only in the urine and lower urinary tract. The specialized capsule containing both macrocrystals and monohydrate powder is designed to achieve sustained drug release, which results in the continuous maintenance of high drug concentration required for the localized bactericidal action.

Dosage and Administration Information

Official Administration Guidelines

Macrofurin (nitrofurantoin) is an oral antibacterial agent intended for administration by the oral route as a capsule or suspension. Strict adherence to the prescribed dosing schedule and administration instructions is required to maintain effectiveness against susceptible bacteria and minimize the risk of drug-resistant organisms.

Dosing and Frequency

The required dosage and frequency depend on the formulation and the use case. For the macrocrystals formulation (Macrodantin), the typical adult dose for acute uncomplicated infections is 50 mg to 100 mg four times a day. For the monohydrate/macrocrystals formulation (Macrobid), the dosage is typically 100 mg twice daily. Treatment courses are generally maintained for seven days or for at least three days after a sterile urine culture is obtained.

Use Case Macrocrystals (e.g., Macrodantin) Monohydrate/Macrocrystals (e.g., Macrobid)
Acute Treatment (Adults) 50–100 mg four times daily 100 mg twice daily
Long-term Suppression (Adults) 50–100 mg once daily (at bedtime) Not typically indicated

Special Conditions and Preparation

All oral forms of Macrofurin must be taken with food or milk to enhance absorption and patient tolerance. For the oral suspension, the liquid must be forcefully shaken before each use to ensure even mixing of the medication. Capsules must be swallowed whole, without crushing, opening, or chewing. If a dose is missed, take it as soon as it is remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped; do not double a dose to compensate.

Recent Clinical Evidence

Macrofurin: Recent Clinical Evidence

Research has explored the use of Macrofurin (nitrofurantoin monohydrate/macrocrystals) as an antibacterial agent primarily for treating acute uncomplicated urinary tract infections (UTIs) caused by susceptible organisms, such as E. coli and Staphylococcus saprophyticus.


Overview of Efficacy Studies

Key evidence comes from randomized controlled trials comparing Macrofurin to other oral antibiotics or placebo in non-pregnant adult women with uncomplicated UTIs. Studies indicate that Macrofurin concentrates rapidly in the urine, which is advantageous for targeting the site of infection.

  • Trial Design: A randomized, double-blind study of women with uncomplicated lower UTIs compared a five-day course of Macrofurin (100 mg three times daily) against a single dose of fosfomycin.

  • Primary Outcome: The trial examined clinical and microbiological resolution at 28 days following therapy. Clinical resolution was reported to be significantly greater in the Macrofurin group (70%) compared to the fosfomycin group (58%) in the patient population studied.

Clinical and Bacteriological Outcomes

Outcome Examined Key Finding (vs. Comparator)
Clinical Resolution Observed to be higher with Macrofurin at 28 days compared to single-dose fosfomycin.
Bacteriological Cure Microbiological resolution was also reported to be higher with Macrofurin compared to fosfomycin.
Resistance Patterns Long-term data suggest that the development of acquired bacterial resistance to nitrofurantoin has not been a significant issue, possibly due to its broad-based mechanism of action.

Safety and Research Limitations

Common adverse events reported in clinical trials were primarily gastrointestinal, including nausea, headache, and flatulence. Researchers also note that the drug lacks broader tissue distribution compared to some other therapeutic agents, which may lead to persistence or reappearance of bacteria in some cases. Further robust studies are necessary to evaluate its comparative long-term effectiveness against emerging pathogens.

Frequently Asked Questions (FAQ)

Common questions about Macrofurin (FAQ)

Q: How quickly does Macrofurin start working for a bladder infection?

Macrofurin concentrates its effect in the urine and lower urinary tract soon after administration, leading to rapid bactericidal effects. While initial symptom relief may be felt quickly, the full duration of therapy must be maintained as prescribed. This helps ensure that the infection is fully eradicated, according to regulatory guidelines.


Q: What are the most common side effects of taking Macrofurin?

According to official regulatory information, the most frequently reported adverse effects are generally digestive. These include nausea, headache, vomiting, flatulence, and diarrhea. These common reactions are generally mild, but any symptoms that are concerning or persistent should be reported to a healthcare professional.


Q: How long after starting Macrofurin should symptoms begin to improve?

Clinical improvement time can vary depending on the severity of the infection. While many people experience symptom relief within a few days, the full treatment course is usually maintained for about seven days. The entire prescribed course must be completed, as this helps achieve the intended therapeutic effect and minimize the risk of recurrence.


Q: What happens if you suddenly stop taking Macrofurin before the course is finished?

Stopping any antibacterial medication early can increase the risk of the infection recurring. It may also promote the development of antibiotic-resistant bacteria, meaning the drug may not work as effectively in the future. It is important to continue the medication exactly as prescribed until the full course is completed.


Q: Why is it important to take Macrofurin with food?

Regulatory information specifies that Macrofurin must be taken with food or milk. This administration method is required to enhance the absorption of the medicine into the body and to improve patient tolerance, which can help minimize common gastrointestinal side effects.


Q: Can Macrofurin affect the results of any lab tests?

Yes, Macrofurin may interfere with some laboratory procedures. Specifically, it can cause a false positive result for glucose (sugar) in the urine when tested using older copper reduction methods. This interference does not typically occur with modern enzymatic glucose tests.


Q: How is Macrofurin different from Cipro or Bactrim?

Macrofurin is a nitrofuran antibacterial agent, which means it works differently from common broad-spectrum antibiotics like quinolones (Cipro) or sulfa drugs (Bactrim). Macrofurin is highly targeted and achieves its effective concentration almost exclusively in the urine, focusing its therapeutic action in the lower urinary tract.


Q: What's the typical duration of treatment with Macrofurin?

The typical duration of treatment for acute uncomplicated infections is generally 7 days. A healthcare provider will determine the exact duration, but treatment is maintained long enough to ensure the bacteria are fully eliminated, as outlined in official administration guidelines.


Q: Is Macrofurin the same as other nitrofurantoin brands?

Macrofurin is a brand name for the active ingredient nitrofurantoin. This ingredient is available under different brands and in various formulations, such as the macrocrystals or the dual-release blend. While the active component is the same, these different formulations may have unique dosing schedules.


Q: Are there different forms of Macrofurin, like capsules versus tablets?

Macrofurin is typically supplied as a hard gelatin capsule containing a specialized dual-release blend of the medicine. It is also available as an oral suspension (liquid form). Standard tablet formulations are not typically listed for this specific type of nitrofurantoin preparation.


Q: Can Macrofurin make your urine a strange color?

Official product information notes that the urine may turn a darker yellow or brownish color during treatment. This is considered an anticipated, non-harmful effect of the medication.


Q: Is it normal to feel dizzy or lightheaded while on Macrofurin?

Dizziness and lightheadedness have been reported as possible adverse events in patients taking Macrofurin. Due to this potential side effect, caution is generally recommended when driving or operating machinery until the effects are known.


Q: Does Macrofurin interact with common vitamins or supplements?

Official labeling highlights specific interactions with drugs like certain antacids and uricosuric agents. Interactions with common vitamins or supplements are not listed as major warnings, and it is recommended to inform a healthcare provider about all current supplements being taken.


Q: How long does Macrofurin stay in your system after you stop taking it?

Macrofurin has a relatively short half-life and is rapidly eliminated, with a significant amount of the dose recovered from the urine within 24 hours. Due to this rapid elimination, strict adherence to the prescribed dosing schedule is important throughout the treatment course.


Q: Can Macrofurin cause fatigue or tiredness?

Adverse events such as fatigue, weakness (asthenia), and drowsiness have been reported in association with the use of Macrofurin. If these effects are unusual or severe, they should be reported to a healthcare professional.


Q: Is Macrofurin used to treat infections in other parts of the body?

No. Macrofurin is indicated only for the treatment of urinary tract infections. This is because the drug does not achieve effective concentrations in the blood or in body tissues outside of the urinary tract, making it a highly localized therapy.


Q: Does Macrofurin work against antibiotic-resistant bacteria?

Macrofurin is indicated only for infections caused by strains of bacteria that are susceptible to it. Regulatory data suggests that the development of acquired resistance to nitrofurantoin has been reported to be relatively rare.


Q: Can Macrofurin cause headaches?

Yes, headache is one of the commonly occurring adverse effects that has been reported with the use of Macrofurin, according to official safety information.


Q: Is it okay to take Macrofurin if you have liver disease?

Macrofurin is contraindicated (must not be used) if there is a history of specific liver issues, such as cholestatic jaundice, caused by previous nitrofurantoin use. Serious hepatotoxicity has been reported, and use in patients with existing liver disease requires cautious management.


Q: Can I take Macrofurin if I am lactose intolerant?

Official labeling indicates that some formulations of Macrofurin (nitrofurantoin macrocrystals) may contain lactose as an inactive ingredient. Individuals with lactose intolerance should consult their pharmacist to confirm the ingredients of their specific prescription.


Q: What precautions should be taken when storing Macrofurin?

Macrofurin must be stored in a tight, light-resistant container at controlled room temperature. It is critical to keep the medication away from light, moisture, excessive heat, and especially out of the sight and reach of children.


Q: Can Macrofurin cause tingling or numbness in the hands or feet?

Yes, peripheral neuropathy (nerve damage), which can present as tingling or numbness, has been reported. This risk may be higher in individuals with pre-existing conditions like severe renal impairment or diabetes. Patients are advised to report these symptoms promptly.


Q: Does Macrofurin contain any penicillin or sulfa drugs?

No. Macrofurin's active ingredient, nitrofurantoin, is chemically classified as a nitrofuran antibacterial agent. It is a synthetic compound and does not contain ingredients from the penicillin or sulfa drug classes.


Q: Is Macrofurin effective against all types of urinary infections?

No. Macrofurin is indicated only for infections caused by specific, susceptible strains of bacteria, such as E. coli and Staphylococcus saprophyticus. It is generally not effective against organisms like most strains of Proteus or Pseudomonas species.


Q: Does the time of day matter when taking Macrofurin?

For long-term preventative use (suppression), a common dosage is prescribed once daily, typically taken at bedtime. For acute treatment, the medication is taken multiple times per day, and the prescribed schedule should be followed consistently.


Q: Can Macrofurin be taken if I have diabetes?

Because diabetes mellitus may increase the risk of peripheral neuropathy, the use of Macrofurin in patients with diabetes requires cautious management by a healthcare provider.


Q: What are the less common, but possible, lung-related side effects of Macrofurin?

Official labeling highlights the potential for serious pulmonary (lung) hypersensitivity reactions, which can occur in acute, subacute, or chronic forms. Chronic reactions, which may involve lung scarring, are generally associated with use lasting six months or longer.


Q: How does Macrofurin target bacteria without harming healthy cells?

Macrofurin's action is specialized because it is activated only inside bacterial cells by specific bacterial enzymes. Furthermore, its effect is localized, achieving therapeutic concentrations primarily in the urine and lower urinary tract, which helps avoid widespread systemic distribution.

How should Macrofurin be stored and disposed of?

Official Storage Requirements

Macrofurin (nitrofurantoin) must be stored at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The regulatory labeling mandates protection from moisture and light, and the product must be kept away from excessive heat and protected from freezing.

The medication should be kept in a tight, light-resistant container and stored out of the sight and reach of children.

Disposal Instructions

Outdated or unused medicine should not be kept. Regulatory guidelines instruct users to ask a healthcare professional or pharmacist how to dispose of any remaining medication properly. Unused medication must not be disposed of by throwing it into household waste or down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Macrofurin found in:

A-Z Index: